Physician profile
David Greenman
NPI 1801850342
$6,229.78
in general payments reported to CMS, 2019-2025
36 companies · $911 in 2025
The $911 reported for 2025 was more than what 75% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $85.73 · 2021: $463 · 2022: $1,069 · 2023: $991 · 2024: $2,316 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,866 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,250 · Entertainment: $62.06 · Education: $40.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,865.70 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,250.00 |
| Entertainment | $62.06 |
| Education | $40.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,494.00 | 2022-2025 | Xiidra, Miebo, Stellaris Elite |
| Regeneron Healthcare Solutions, INC. | $621.93 | 2019-2025 | Eylea Hd, Eylea |
| Alcon Vision LLC | $474.65 | 2019-2025 | Ngenuity, Luxor, Rocklatan |
| Abbvie INC. | $448.21 | 2022-2025 | |
| Astellas Pharma US INC | $401.85 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $297.49 | 2019-2023 | |
| Amgen INC. | $213.72 | 2024-2025 | Tepezza |
| Allergan, INC. | $213.55 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $201.42 | 2022-2024 | Syfovre |
| Genentech USA, INC. | $184.39 | 2019-2023 | Vabysmo |
| Alimera Sciences, INC. | $171.54 | 2019-2024 | Iluvien, Yutiq |
| Sun Pharmaceutical Industries INC. | $166.00 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $165.62 | 2022-2024 | Acthar |
| Aerie Pharmaceuticals, INC. | $160.26 | 2019-2021 | |
| Oyster Point Pharma, INC. | $99.61 | 2022-2024 | Tyrvaya, Ryzumvi |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $94.78 | 2023 | Tepezza |
| Coherus Oncology, INC. | $93.88 | 2023-2024 | |
| Rxsight INC | $70.53 | 2023 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Light Adjustable Lens (Rxlal) |
| Notal Vision, INC. | $67.70 | 2024 | Foresee Home |
| Ani Pharmaceuticals, INC. | $65.45 | 2025 | Iluvien, Yutiq |
| Optos, INC. | $62.06 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Glaxosmithkline, LLC. | $58.48 | 2022-2025 | Blenrep |
| Eyepoint US, INC. | $52.89 | 2019-2023 | |
| Biotissue Holdings INC. | $48.75 | 2022-2023 | |
| Harrow Eye, LLC | $45.52 | 2025 | Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $42.18 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $33.31 | 2024 | Xdemvy |
| Sandoz INC. | $33.30 | 2025 | Cimerli |
| Merz Pharmaceuticals, LLC | $27.72 | 2023 | Xeomin |
| Sight Sciences, INC. | $25.07 | 2022 | |
| Vanda Pharmaceuticals INC. | $18.95 | 2019 | |
| Dompe US, INC. | $17.03 | 2022 | |
| Omeros Corporation | $16.47 | 2021 | |
| Ocular Therapeutix, INC. | $14.67 | 2019 | |
| Rayner Intraocular Lenses Limited | $13.55 | 2025 | Omidria |
| Carl Zeiss Meditec USA, INC. | $13.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Greenman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.